GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bioretec Ltd (OHEL:BRETEC) » Definitions » Return-on-Tangible-Equity

Bioretec (OHEL:BRETEC) Return-on-Tangible-Equity : -55.28% (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Bioretec Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Bioretec's annualized net income for the quarter that ended in Jun. 2024 was €-3.77 Mil. Bioretec's average shareholder tangible equity for the quarter that ended in Jun. 2024 was €6.82 Mil. Therefore, Bioretec's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2024 was -55.28%.

The historical rank and industry rank for Bioretec's Return-on-Tangible-Equity or its related term are showing as below:

OHEL:BRETEC' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -240.68   Med: -87.16   Max: -46.73
Current: -46.73

During the past 6 years, Bioretec's highest Return-on-Tangible-Equity was -46.73%. The lowest was -240.68%. And the median was -87.16%.

OHEL:BRETEC's Return-on-Tangible-Equity is ranked worse than
73.39% of 759 companies
in the Medical Devices & Instruments industry
Industry Median: 2.12 vs OHEL:BRETEC: -46.73

Bioretec Return-on-Tangible-Equity Historical Data

The historical data trend for Bioretec's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioretec Return-on-Tangible-Equity Chart

Bioretec Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial - - -240.68 -87.16 -82.01

Bioretec Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -80.71 -99.45 -75.72 -39.83 -55.28

Competitive Comparison of Bioretec's Return-on-Tangible-Equity

For the Medical Devices subindustry, Bioretec's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioretec's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bioretec's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Bioretec's Return-on-Tangible-Equity falls into.



Bioretec Return-on-Tangible-Equity Calculation

Bioretec's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-3.789/( (1.494+7.746 )/ 2 )
=-3.789/4.62
=-82.01 %

Bioretec's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jun. 2024 )  (Q: Dec. 2023 )(Q: Jun. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jun. 2024 )  (Q: Dec. 2023 )(Q: Jun. 2024 )
=-3.768/( (7.746+5.886)/ 2 )
=-3.768/6.816
=-55.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jun. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Bioretec  (OHEL:BRETEC) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Bioretec Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Bioretec's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioretec Business Description

Traded in Other Exchanges
Address
Yrittajankulma 5, Tampere, FIN, FI-33710
Bioretec Ltd is a medical device company focusing on the development of safe, and reliable bioabsorbable and bioresorbable implants for pediatric and adult orthopedics. The company's products are used world wide and continue to further develop materials and products for high-load-bearing clinical applications. Some of its brands include RemeOs, Activa IM-N, ActivaPi, and ActivaScrew.

Bioretec Headlines

No Headlines